The current evidence of retrospective studies shows a higher risk of ILD and other severe trAEs in the use of osimertinib immediately (within 180 days) after nivolumb [38,39] or other PD-L1 antibodies [37]. The gene discussed is CD274; the disease is interstitial lung disease.